← All trials
NCT02023333
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2013
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Dec 30, 2013
- Last posted
- Nov 1, 2022
- Enrollment
- 11
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- BayerCollaborator
- City University of New YorkCollaborator
- State University of New York, BrooklynCollaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.